Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is based in Boca Raton, Florida.
SRTS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sensus Healthcare Inc. To summarize, we found that Sensus Healthcare Inc ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. The most interesting components of our discounted cash flow analysis for Sensus Healthcare Inc ended up being:
The company's debt burden, as measured by earnings divided by interest payments, is -399.33; that's higher than only 1.44% of US stocks in the Healthcare sector that have positive free cash flow.
Its compound free cash flow growth rate, as measured over the past 0.5 years, is -1% -- higher than only 0% of stocks in our DCF forecasting set.
The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately only 13.4% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
AGHC, ALC, AMRN, ATRS, and MOR can be thought of as valuation peers to SRTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Influential professional organization recommends radiotherapy as the primary non-surgical alternative for patients with basal cell or cutaneous squamous cell carcinomasBOCA RATON, Fla, July 14, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, and the leading provider of superficial radiotherapy (SRT), reports that new guidelines issued by the American Society for Radiation Oncology (ASTRO) recommends SRT as the first-line alternative to surgery when treating patients with non-melanoma skin cancer (NMSC). With more than 10,000 members, ASTRO is the world’s premier radiation oncology society and the authority on radiation therapy.“Over th...
BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.Sensus will participate in a panel discussion on Re-Engaging Medical Practices in an Era of COVID-19. As the country slowly begins to re-open, information is imperative. How and when will medical practices re-open, and to what extent? Will pent-up demand recoup some of the lost revenue? What are doctors observing as they re-engage with patie...